TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer

Neeraj Agarwal1 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT84112, USACorrespondence[email protected]

Fred Saad2 University of Montréal Hospital Center, Montréal, Québec, H2L 4M1, Canada

Arun A Azad3 Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia

Joaquin Mateo4 Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, 08035, Barcelona, Spain

Nobuaki Matsubara5 National Cancer Center Hospital East, Chiba, 277-8577, Japan

Neal D Shore6 Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA

Jayeta Chakrabarti7 Pfizer Ltd., Tadworth, Surrey, KT20 7NS, UK

Hsiang-Chun Chen8 Pfizer Inc., La Jolla, CA92121, USA

Silvana Lanzalone9 Pfizer Oncology, Milan, 20152, Italy

Alexander Niyazov10 Pfizer Inc., New York, NY, 10012, USA

Karim Fizazi11 Institut Gustave Roussy, University of Paris Sud, Villejuif, 94800, France

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.